Summary
Project Summary Alzheimer's disease (AD) is the sixth leading cause of death in United States, yet this indication lacks truly effective therapeutics to mitigate this disease. To develop novel and effective therapies, a novel (partial) Liver-X-receptor (LXR) β and peroxisomal proliferator activating– gamma (PPARγ) nuclear receptor agonist (AU403) that has selective amino acid interactions in the receptor ligand-binding domain was developed. Preliminary data suggest AU403 may reduce AD-related pathologies, including amyloid accumulation, behavioral deficits and neurodegeneration (reduced
